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Rheumatoid arthritis (RA) is an autoimmune dis-
ease that causes inflammation of the joints. It has 
a strong impact on people’s everyday lives. 
Patients with RA suffer from pain, limited mobil-
ity and disability and experience a decreased 
quality of life (Matcham et al., 2014). The course 
of disease is chronic and often progressive. 
Current pharmacological treatment regimes can 
control the symptoms of RA and – when applied 
during early stages of the disease – have the 
potential to slow down the progression of the 
disease (Smolen and Aletaha, 2015). However, 
non-adherence to the prescribed medication is 
Depression moderates the 
associations between beliefs  
about medicines and medication 
adherence in patients with 
rheumatoid arthritis:  
Cross-sectional study
Susanne Brandstetter1, Gertraud Riedelbeck1, 
Mark Steinmann1, Julika Loss1, Boris Ehrenstein2 
and Christian Apfelbacher1
Abstract
The ‘necessity–concerns framework’ postulates that patients’ adherence behaviour is influenced by beliefs 
about the necessity and the concerns patients have regarding their prescribed medicines. We hypothesized 
that depression moderates the associations between beliefs about medicines and medication adherence 
among people with rheumatoid arthritis. Using multivariate logistic regression, we observed that people 
experiencing more depressive symptoms showed stronger associations between necessity beliefs and 
adherence as well as attenuated associations between concerns and adherence, respectively, in a cross-
sectional sample (N  =  361). Thus, depression moderates the associations postulated in the ‘necessity–
concerns framework’ in a differential way in people with rheumatoid arthritis.
Keywords
beliefs about medicines, depression, medication adherence, rheumatoid arthritis
1University of Regensburg, Germany
2Asklepios Medical Center Bad Abbach, Germany
Corresponding author:
Susanne Brandstetter, Medical Sociology, Institute of 
Epidemiology and Preventive Medicine, University of 
Regensburg, Dr.-Gessler-Str. 17, 93051 Regensburg, 
Germany. 
Email: susanne.brandstetter@klinik.uni-regensburg.de
646440 HPQ0010.1177/1359105316646440Journal of Health PsychologyBrandstetter et al.
research-article2016
Article
2 Journal of Health Psychology 
highly prevalent in RA, as in many other chronic 
conditions. According to a review conducted by 
van den Bemt et al. (2012), 30–80 per cent of 
patients with RA are not adherent. A large body 
of studies investigated the factors which could 
potentially influence medication adherence in 
RA. Two reviews have revealed that neither soci-
odemographic nor disease- or therapy-related 
factors were consistently associated with medi-
cation adherence, rather psychosocial factors 
were considered as crucial (Vangeli et al., 2015; 
van den Bemt et al., 2012).
There are various theoretical models which 
seek to describe and explain medication non-
adherence with a focus on psychological con-
structs. The ‘necessity–concerns framework’ 
(Horne and Weinman, 1999) suggests that 
patients’ adherence behaviour depends on the 
perceived necessity of medicines and on the 
concerns patients might have regarding their 
medication. It has been shown that these beliefs 
about medicines are associated with patients’ 
extent of medication adherence. A systematic 
review and meta-analysis conducted by Horne 
et al. (2013) demonstrated that stronger beliefs 
about the necessity of medicines were associ-
ated with higher medication adherence and 
stronger concerns regarding medicines with 
lower adherence among patients with chronic 
conditions. Studies have demonstrated these 
associations also for patients with RA (De 
Thurah et al., 2010; Neame and Hammond, 
2005; Nestoriuc et al., 2010; Spruill et al., 2014; 
Treharne et al., 2004; van den Bemt et al., 2009; 
Zwikker et al., 2014). However, little is known 
as to whether the strength of the observed asso-
ciations between beliefs about medicines and 
adherence varies with patients’ characteristics, 
that is, whether the associations are moderated 
by third factors such as comorbidities. This 
knowledge about how patients’ characteristics 
could moderate the associations between beliefs 
about medicines and medication adherence 
seems crucial when developing and targeting 
future interventions.
One very common comorbidity in RA is 
depression. A major depressive disorder accord-
ing to established diagnostic criteria is prevalent 
in about 17 per cent of patients with RA 
(Matcham et al., 2013). Self-reported depressive 
symptoms are even more prevalent (Dougados 
et al., 2014; Matcham et al., 2013). The presence 
of depression can alter the course of RA nega-
tively via cognitive-behavioural or inflamma-
tory pathways: patients with concurrent 
depression suffer from more pain, show a 
heightened disease activity (Rathbun et al., 
2013) as well as generally poorer health out-
comes (Morris et al., 2011). Some specific char-
acteristics of people suffering from depression, 
such as negatively biased (social) cognitions or 
motivational deficits, can affect behaviours and 
the way in which cognitions shape behaviours 
(Weightman et al., 2014; Wisco and Nolen-
Hoeksema, 2010). This suggests consequences 
for adherence behaviours: DiMatteo et al. (2000) 
analysed the relationship between depression 
and adherence to various treatment regimes and 
found depression to contribute to medication 
non-adherence among patients with different 
medical conditions. This has also been shown 
for patients with RA (Cabrera-Marroquin et al., 
2014), even if a systematic review on depression 
and treatment discontinuation among patients 
with RA found the existing results to be incon-
clusive (Rathbun et al., 2013). In order to foster 
the understanding of medication adherence in 
RA and the applicability of the ‘necessity–con-
cerns framework’, the investigation of the role 
of depression seems to be a key issue.
Therefore, the aim of this study was to ana-
lyse whether depression moderates the associa-
tion between beliefs about medicines and 
medication adherence in patients with RA. It 
was hypothesized that the postulated associa-
tions (stronger necessity beliefs and higher 
adherence, weaker concerns and higher adher-
ence) would be attenuated with higher depres-
sion scores.
Methods
This cross-sectional study is part of a longitudi-
nal study on medication adherence in patients 
suffering from RA. The study was conducted at 
the Department of Rheumatology, Asklepios 
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Medical Center Bad Abbach, a tertiary care 
centre for patients with autoimmune and rheu-
matic diseases, located in the south of Germany.
Patients and recruitment
Patients were eligible for participation in the 
study if they were aged 18 years or older, had 
physician-diagnosed RA and were currently 
under medical treatment for RA. They were 
approached during an inpatient hospital stay or 
an outpatient visit and asked to provide 
informed consent for participation in the study. 
Recruitment took place over the course of 
14 months. Patients were excluded from the 
study if they were aged less than 18 years, if 
they had a psychiatric diagnosis other than 
affective disorders or if they were unable to 
understand German. Finally, 361 patients with 
RA were included. The study has been approved 
by the ethics committee of University of 
Regensburg (file-number: 12-101-0126).
Measures and data collection
All participating patients were asked to com-
plete self-report questionnaires. Additional 
information was extracted from patients’ (elec-
tronic) health records.
Medication adherence was assessed using the 
‘Medication Adherence Report Scale’ (MARS; 
German version: Mahler et al., 2010). It com-
prises five items on intentional and non-inten-
tional adherence behaviours. Each item is scored 
on a 5-point Likert scale ranging from ‘1 = never’ 
to ‘5 = always’. A sum score was calculated. In 
our sample, the resulting distribution was highly 
positively skewed; thus, we dichotomized the 
MARS score with values lower than 25 indicat-
ing non-adherence or incomplete adherence and 
the value 25 indicating complete adherence. The 
dichotomization with this cut-off score was used 
for all analyses presented in this article. 
Additionally, we performed sensitivity analyses 
using other cut-off values (⩾23; ⩾24) (data not 
shown). This strategy was applied as there is no 
agreement in the literature on a cut-off value 
when dichotomizing the MARS, and sensitivity 
analyses can help assuring the robustness of 
findings.
Patients’ beliefs about medicines were meas-
ured using two scales of the ‘Beliefs about 
Medicines Questionnaire’ (BMQ; Horne et al., 
1999; German version: Mahler et al., 2012). 
The scale ‘necessity’ consists of five items 
assessing patients perceived necessity regard-
ing their prescribed medicines (e.g. ‘I could not 
live without my medicines’), the scale ‘con-
cerns’ comprises six items on patients’ concerns 
about their medicines (e.g. ‘Sometimes I worry 
about my medicines’). All items are scored on a 
5-point Likert scale (ranging from ‘I strongly 
agree’ to ‘I strongly disagree’). Scale values are 
calculated as means with higher values indicat-
ing stronger beliefs.
The depression scale of the ‘Hospital 
Anxiety and Depression Scale’ (HADS; 
Zigmond and Snaith, 1983) was used to screen 
for symptoms of depression. The sum score 
ranges from 0 to 21, with higher values indicat-
ing the presence of more depressive symptoms. 
Different thresholds have been proposed for the 
HADS. We used the conventional cut-offs of 8+ 
(indicating a probable depression) and 11+ 
(indicating depression) (Zigmond and Snaith, 
1983).
Data on current medication were obtained 
from patients’ health records. All prescribed 
medications were assessed and categorized 
according to type of medication (non-steroidal 
anti-inflammatory drugs (NSAIDs), opioids, 
corticosteroids, disease-modifying antirheu-
matic drugs (DMARDs), biologicals and non-
RA medication).
The ‘28-joint Disease Activity Score’ (DAS28) 
was used to assess disease severity (Wells et al., 
2009). It combines clinical (e.g. number of 
affected joints) and laboratory (C-reactive protein 
(CRP)) parameters with patients’ perception of 
disease severity during the course of the past 
7 days. The scoring was performed according to 
the published algorithms with higher values indi-
cating higher disease activity.
Information on patients’ sociodemographic 
background was obtained by questionnaire. The 
items captured sex, age, educational background, 
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migration background and living situation. 
Additional items referred to disease characteris-
tics: age at time of diagnosis, distance to the pro-
vider of RA treatment and the experience of 
severe side effects due to RA medication.
Both data gathered by questionnaires from 
patients and data on current medication 
extracted from health records were entered 
twice and cross-checked in order to assure data 
quality.
Statistics
Descriptive statistics were calculated using fre-
quencies and percentages or means (M) and 
standard deviations (SD). Group differences 
were determined by t tests or χ2 tests.
In order to test whether depression moder-
ates the association between beliefs about med-
icines and medication adherence, multivariate 
logistic regression analyses were computed for 
both the ‘necessity’ and the ‘concerns’ subscale, 
each including an interaction term with depres-
sion. This approach refers to a multiplicative 
interaction model. Predictor variables were 
transformed by grand mean centring. If the 
interaction term was significant, simple slope 
analyses were conducted with slopes for each 
the mean value, the mean value plus 1 SD and 
the mean value minus 1 SD of the moderator 
variable.
A large number of theoretically selected vari-
ables were investigated for inclusion as potential 
confounders of the association between neces-
sity/concerns and adherence by means of uni-
variate analyses with an entry p value of .20. 
Sex, the number of prescribed RA medicines 
and self-rated pain were found to be associated 
with both necessity beliefs and medication 
adherence in univariate analyses. Only the num-
ber of prescribed RA medicines and self-rated 
pain were associated with both concerns and 
medication adherence. These variables were 
thus included as potential confounders in the 
respective analyses.
Collinearity diagnostics were performed 
for both regression models. For both models, 
there was no indication for multicollinearity 
according to the variance inflation factors 
(VIFs), tolerance values and eigenvalues. Thus, 
all variables could be included simultaneously.
Results of the logistic regression analyses 
are given as odds ratios (OR) and 95% confi-
dence intervals (CI). Model fit is reported by 
Nagelkerke’s R2.
p values <.05 were interpreted as statistically 
significant. All analyses were performed using 
SPSS.22, the moderation analyses were per-




Patients’ sociodemographic and disease-related 
characteristics are displayed in Table 1. A total 
of 361 patients with physician-diagnosed RA 
were included in the study, of which about 
30 per cent were male. On average, patients 
were aged 60 years, and RA had been diagnosed 
approximately 11 years ago. The mean number 
of prescribed medicines was seven, including 
on average four prescribed RA medicines. In 
all, 43 per cent of participants reported that they 
had at least once experienced severe side effects 
due to their medication. About one-third of par-
ticipants showed elevated depression scores, 
indicating a probable depression.
Bivariate analyses
In all, 32 per cent of patients were completely 
adherent. Patients’ characteristics stratified 
according to being adherent or non-adherent are 
displayed in Table 1. There were significantly 
fewer men in the group of adherent patients 
(20% compared to 36% in the group of non-
adherent patients, p = .002). Mean HADS-D 
scores were significantly lower among adherent 
patients than among non-adherent patients 
(p = .001). There were no statistically signifi-
cant group differences in any other patient, dis-
ease or treatment-related variables.
Overall, patients held strong beliefs about 
the necessity of medicines and reported only 
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minor concerns. Bivariate analyses showed that 
adherent patients had higher scores on the 
necessity scale than non-adherent patients 
(M = 4.36 (SD = 0.57) vs M = 4.23 (SD = 0.65)). 
However, the difference was not significant. 
Adherent patients had significantly lower 
scores on the concerns scale (M = 2.60 
(SD = 0.84) vs M = 2.94 (SD =0 .75); p < .001).
Moderation analyses
Results from logistic regression analyses are 
presented in Tables 2 and 3.
Necessity beliefs and depression were each 
significantly associated with medication adher-
ence, with stronger necessity beliefs increasing 
(OR = 1.72; 95% CI: 1.08–2.74) and with higher 
depression scores decreasing the chance of 
being adherent (OR = 0.87; 95% CI: 0.81–0.94) 
(see Table 2). The interaction term ‘depres-
sion × necessity’ was also significant (OR = 1.15; 
95% CI: 1.02–1.29). Slope analyses showed that 
the direction of the interaction was contrary to 
the postulated hypothesis: At the mean value of 
depression and 1 SD above, there were signifi-
cant positive associations between necessity 
beliefs and adherence. However, when the 
depression score was low (mean minus 1 SD), 
there was no such association. This moderation 
effect of depression is illustrated in Figure 1(a).
The logistic regression analysis of medication 
adherence on concerns showed no significant 
association of concerns (OR = 0.74; 95% CI: 
0.52–1.06), but the associations of depression 







Male (%) 30.5 19.6 36.0*
Age (years) (M; SD) 60.20 (13.36) 60.31 (13.16) 59.80 (13.32)
Migrational background (%) 7.2 8.9 6.7
Schooling ⩾10 years (%) 39.4 41.8 38.2
BMI (M; SD) 27.75 (5.80) 28.20 (6.22) 27.61 (5.62)
Age at diagnosis (years) (M; SD) 49.26 (15.21) 48.35 (14.74) 49.31 (15.35)
Duration of disease (years) (M; SD) 10.94 (9.22) 11.35 (8.89) 10.82 (9.39)
Inpatient treatment (%) 21.7 18.0 22.6
Distance to provider of RA treatment (km) M; SD) 58.59 (44.75) 59.25 (46.03) 58.24 (44.58)
Experience of severe side effects (% yes) 43.2 39.3 45.2
Number of prescribed medicines (M; SD) 7.13 (3.68) 7.44 (3.80) 6.98 (3.62)
Number of prescribed RA medicines (M; SD) 3.86 (1.60) 4.12 (1.51) 3.77 (1.64)
NSAR (any, %) 16.4 17.1 16.3
Opioids (any, %) 14.4 13.5 15.1
Corticosteroids (any, %) 71.9 75.7 70.3
DMARDs (any, %) 75.8 79.3 74.1
Biologicals (any, %) 29.2 27.9 30.5
Self-rated pain (1-10; M; SD) 4.47 (2.78) 4.62 (2.75) 4.15 (2.84)
DAS28 (M; SD) 3.07 (1.57) 3.00 (1.68) 3.08 (1.53)
HADS depression (M; SD) 6.02 (3.83) 5.01 (3.99) 6.41 (3.62)*
BMQ necessity (M; SD) 4.27 (0.64) 4.36 (0.57) 4.23 (0.65)
BMQ concerns (M; SD) 2.84 (0.80) 2.60 (0.84) 2.94 (0.75)*
Group differences were analysed using χ2 or t-tests.
M: mean; SD: standard deviation; RA: rheumatoid arthritis BMI: body mass index; NSAR: non-steroidal anti-inflammatory 
drug; DMARDs: disease-modifying antirheumatic drugs; DAS28: Disease Activity Score 28; HADS: Hospital Anxiety and 
Depression Scale; BMQ: Beliefs about Medicines Questionnaire.
*p < .05.
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with medication adherence (OR = 0.91; 95% CI: 
0.84–0.98) and the interaction term ‘depres-
sion × concerns’ (OR = 1.08; 95% CI: 1.01–1.16) 
reached statistical significance. Simple slope 
analysis revealed that only in patients with low 
depression scores (mean minus 1 SD), concerns 
were negatively associated with medication 
adherence, while there was no significant asso-
ciation between concerns and adherence among 
patients with mean and high depression scores 
(see Figure 1(b)). These results are in line with 
our hypothesis.
Sensitivity analyses were performed with two 
additional cut-off values to dichotomize the 
MARS score (data not shown). The use of these 
cut-off values resulted in higher proportions of 
patients classified as being adherent (MARS ⩾ 24: 
57.0% and MARS ⩾ 23: 70%). Moderation anal-
yses showed that none of the associations were 
altered in their direction, although some did not 
reach statistical significance.
Discussion
Our study demonstrated that the presence of 
depressive symptoms moderates the relation-
ship between beliefs about medicines and medi-
cation adherence in patients with RA. The 
findings imply that depression can alter the way 
in which beliefs about medicines translate into 
adherence behaviour. However, the results of 
this study did not support the hypotheses on the 
direction of the effects we had formulated. We 
had a priori hypothesized that depression would 
attenuate the associations between beliefs about 
medicines and medication adherence, but this 
was only true for the association between con-
cerns and adherence. Regarding patients’ per-
ceived necessity – contrary to our hypothesis 
– depression was found to strengthen the asso-
ciation. This finding of a differential effect of 
depression warrants thorough discussion.
In this sample, patients generally hold strong 
beliefs about the necessity of their medicines 
and had less pronounced concerns. This is in 
line with results of other studies among patients 
with RA (Nestoriuc et al., 2010; van den Bemt 
et al., 2009; Zwikker et al., 2014) and could 
reflect specifics of the disease, such as the sever-
ity and the impact on participants’ daily lives.
The negative relationship between concerns 
and medication adherence was attenuated in 
patients with moderate depression scores and 
not existing in patients with high depression 
scores. As hypothesized, the presence of depres-
sion may hinder the translation of beliefs into 
behaviours, thus reducing negative impact of 
potential concerns on adherence or making 
them obsolete. Possible explanations refer to 
characteristics of people with depression, such 
as indifference to beliefs and behaviours which 
are stable, rigid and not prone to change (Meiran 
et al., 2011).
Table 2. Moderation analysis of medication 
adherence on depression and necessity.
OR 95% CI p
HADS depression 0.87 0.81; 0.94 .001
BMQ necessity 1.72 1.08; 2.74 .022
Interaction: 
depression × necessity
1.15 1.02; 1.29 .025
OR: odds ratio; CI: confidence interval; HADS: Hospital 
Anxiety and Depression Scale; BMQ: Beliefs about 
Medicines Questionnaire.
Logistic regression analysis of medication adherence 
(Medication Adherence Report Scale (MARS)); predictors 
were mean centred; adjusted for sex, number of 
prescribed rheumatoid arthritis (RA) medicines, self-rated 
pain.
Nagelkerke’s R2 = .13.
Table 3. Moderation analysis of medication 
adherence on depression and concerns.
OR 95% CI p
HADS depression 0.91 0.84; 0.98 .020
BMQ concerns 0.74 0.52; 1.06 .104
Interaction: 
depression × concerns
1.08 1.01; 1.16 .030
OR: odds ratio; CI: confidence interval; HADS: Hospital 
Anxiety and Depression Scale; BMQ: Beliefs about 
Medicines Questionnaire.
Logistic regression analysis of medication adherence 
(Medication Adherence Report Scale (MARS)); predictors 
were mean centred; adjusted for number of prescribed 
rheumatoid arthritis (RA) medicines, self-rated pain.
Nagelkerke’s R2 = .14.
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However, due to the findings on the role of 
depression for the association between beliefs 
about necessity of medicines and medication 
adherence, these assumptions about the underly-
ing causes cannot be upheld: the association of 
necessity beliefs and adherence was basically 
attributable to persons with moderate or high 
depression scores, whereas there was no associa-
tion in people with low depression scores. This 
finding suggests that necessity beliefs are crucial 
for adherence in patients who experience depres-
sive symptoms, but only in them. There are two 
possible explanations: one could refer to depres-
sive patients’ motivational difficulties in engag-
ing in behaviours that are not perceived as 
absolutely necessary or urgent. While people 
without depressive symptoms might have suc-
ceeded in behaving adherently even if necessity 
beliefs were low, people with depression might 
be reliant on the perception of high necessity for 
successfully implementing a behaviour. Another 
reason might be that during depressive episodes, 
people experience a heightened susceptibility for 
negatively connotated attitudes and negatively 
framed expectancies which have impact on the 
manifestation of non-adherent behaviours. (Low 
scores on the necessity scale stem from refusals 
to statements such as ‘My medicines protect me 
from becoming worse’ or ‘My health in the 
future will depend on my medicines’.)
However, both explanations contradict the 
idea our initial hypothesis was built upon, that 
is, the attenuation of the relationship between 
necessity beliefs and medication adherence by 
depression due to the non-translation of attitudes 
into behaviours among people with depressive 
symptoms.
Instead, explanations for the differential 
effect of moderation by depression are needed. 
First, there may be common underlying con-
structs which manifest in high concerns about 
medications and high depression scores, such as 
negative affectivity or anxiety. Therefore, we 
did find some empirical overlap between the 
‘concerns’ and the ‘depression’ scales, but this 
did not result in any negative impact on regres-
sion modelling. Assuming that depression and 
strong concerns frequently co-occur, there 
might be only low variance in depressive peo-
ple’s concerns regarding their medicines. This 
Figure 1. Depression as moderator of the association between necessity (a)/ concerns (b) and 
adherence.
Simple slopes equations of the regression necessity/concerns and medication adherence at three levels of depression. 
Medication adherence is expressed as the probability (p) of complete adherence (MARS = 25).
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could explain the attenuated association 
between concerns and medication adherence 
among people with depression.
Second, among people without depression, 
strong beliefs about the necessity of medicines 
held by them may have hindered the association 
between necessity beliefs and medication 
adherence becoming salient. At the same time, 
necessity beliefs that vary more strongly among 
people with depression could have been the pre-
requisite for the emergence of the association 
with medication adherence.
Third, when comparing the associations 
‘necessity–adherence’ and ‘concerns–adher-
ence’, one must consider that these two BMQ 
scales did not only cover different types of 
beliefs but also beliefs of positive (‘necessity’) 
and negative (‘concerns’) valence. It has been 
argued that opposite valences are associated 
with distinct motivational and behavioural 
pathways and that the (non-)correspondence in 
valences of attitudinal measures and behaviours 
can impact the size of their relationships 
(Richetin et al., 2011).
To the best of our knowledge, the ‘necessity–
concerns framework’, that is, the prediction of 
adherence by beliefs about medicines, has not 
yet been investigated with focus on the potential 
moderating role of depression (or of another 
psychosocial variable). Regarding samples of 
patients with RA, only two studies have been 
performed on the ‘necessity–concerns frame-
work’ which even explored depression, albeit it 
was accounted for only as a covariate. Zwikker 
et al. (2014) assessed the HADS score in their 
sample. They found that when including the 
HADS score (and other psychological variables) 
as covariates, the relationship between beliefs 
about medicines and medication adherence 
remained nearly unchanged. Unfortunately, they 
only used the overall score of the HADS, which 
combines symptoms of anxiety and depression, 
and thus, results of the study can hardly be com-
pared with ours. Nestoriuc et al. (2010) investi-
gated the effects of beliefs about medicines on 
self-reported side effects and also found depres-
sion not to contribute to the prediction of side 
effects by beliefs about medicines.
We consider the analysis of depression as a 
moderator for the association of beliefs about 
medicines and medication adherence worthwhile 
as it goes along with implications for both patient 
care and research: Depression is a very common 
comorbidity, not only of RA, but of many chronic 
conditions. It has been postulated to develop 
interventions based on the ‘necessity–concerns 
framework’ which address beliefs that hinder 
adherent behaviour. Some recent research pro-
jects have already engaged in the development of 
this kind of interventional measures for patients 
with RA (Zwikker et al., 2012). With regard to 
our findings, it might be crucial to specifically 
target patients with concurrent depression within 
the population of RA patients as the way in 
which beliefs about medicines impact on adher-
ence behaviour could be altered among those 
patients. The findings of this study would sug-
gest emphasizing the role of necessity beliefs 
among RA patient with concurrent depression. 
Embracing a broader perspective, we propose 
further work which helps disentangling the asso-
ciations within the ‘necessity–concerns frame-
work’. If depression emerged as a crucial factor 
in various studies and across different patient 
populations, one could consider modifying or 
expanding the framework in order to increase 
applicability and validity.
Limitations
This study has some limitations. First, the 
results reported here are cross-sectional associ-
ations, and no conclusions on causality can be 
drawn.
Second, we had to rely on self-report meas-
ures of medication adherence and depression. 
Patients’ medical records which are held in hos-
pitals cover only data on prescribed medication 
but not information on whether prescriptions 
were actually filled. Information on physician-
diagnosed major depression was also not avail-
able, nor was the conduct of a diagnostic 
interview feasible in our study. The HADS-D 
scale is an assessment instrument incorporating 
the potential flaws of self-report measurement. 
Thus, social desirability cannot be excluded, 
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and altered response behaviour due to the pres-
ence of depressive symptoms could be an issue. 
Furthermore, it has been argued that the HADS’ 
latent structure may be unclear and that its 
depression scale may not cover all relevant 
symptoms of depression (the main criticism 
being that it ignores somatic symptoms) (Cosco 
et al., 2012). However, it is still commonly used 
and may be useful and relevant as a screening 
tool.
Third, some of the patients with heightened 
HADS scores could have received pharmacologi-
cal treatment for depression. It would have been 
interesting to differentiate between untreated and 
treated depression.
Finally, patients were recruited only at one 
clinic specialized in the treatment of people 
with RA. As non-adherence may be a particular 
problem in patients who do not receive optimal 
treatment, these results cannot be transferred to 
RA patients in general. However, even if the 
sampling procedure was not designed to yield a 
representative sample of patients with RA, the 
characteristics of our sample regarding the dis-
tribution of sex, age and social status corre-
sponded to the sample characteristics of a 
population-based representative study con-
ducted in Germany (Fuchs et al., 2013). With 
about one-third of RA patients having HADS-D 
scores above the cut-off value, this proportion 
was also in line with data from other studies 
which likewise applied the HADS-D scale and 
the same cut-off value (Covic et al., 2012; 
Matcham et al., 2013).
Conclusion
This study was the first to explore the role of 
depression in the relationship between beliefs 
about medicines and medication adherence in 
patients with RA. The finding of a differential 
effect of depression is highly relevant as it 
informs projects which develop interventions to 
alter beliefs about medicines and as depression 
is a common comorbidity not only in RA but 
also in many other chronic conditions. Further 
research, preferably using longitudinal designs 
with data on the course of depression, is 
necessary to confirm our finding on the role of 
depression and to investigate whether incidence 
and remission of depressive episodes have an 
impact on the associations postulated in the 
‘necessity–concerns framework’.
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